Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Jentadueto is a prescription combination of linagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin hydrochloride, a biguanide. It is used with diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Current tablets contain 2.5 mg of linagliptin with 500 mg, 850 mg, or 1000 mg of metformin hydrochloride.
read more about jentadueto ...Linagliptin inhibits DPP-4 and increases active incretin hormone concentrations, which increases glucose-dependent insulin release and decreases glucagon secretion. Metformin lowers hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
Jentadueto is used in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. It is not recommended for type 1 diabetes. Treatment is contraindicated when estimated glomerular filtration rate is below 30 mL per minute per 1.73 square meters, and initiation is not recommended when the rate is between 30 and 45.
Jentadueto is taken twice daily with meals. Patients not currently taking metformin usually start with 2.5 mg of linagliptin and 500 mg of metformin twice daily. The maximum dose is 2.5 mg of linagliptin and 1000 mg of metformin twice daily. Kidney function is checked before treatment and periodically afterward.
Jentadueto carries a boxed warning for metformin-associated lactic acidosis, which can be fatal. Other serious concerns include pancreatitis, low blood glucose when combined with insulin or insulin secretagogues, severe hypersensitivity, vitamin B12 deficiency, severe joint pain, bullous pemphigoid, and heart failure risk associated with the DPP-4 inhibitor class.
Jentadueto improves glycemic control in adults with type 2 diabetes mellitus when used with diet and exercise.
Jentadueto is taken twice daily with meals.
The maximum dose is 2.5 mg of linagliptin and 1000 mg of metformin twice daily.
Yes. The boxed warning concerns metformin-associated lactic acidosis.
Initial Combination of Linagliptin and Metformin Improves Glycaemic Control in Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study. https://pubmed.ncbi.nlm.nih.gov/22356132/. Date Accessed October 6, 2026.
Initial Combination of Linagliptin and Metformin in Patients With Type 2 Diabetes: Efficacy and Safety in a Randomised, Double-Blind 1-Year Extension Study. https://pubmed.ncbi.nlm.nih.gov/24118640/. Date Accessed October 6, 2026.
JENTADUETO (Linagliptin and Metformin Hydrochloride) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6dd9b86-0d18-95d4-2bc7-05591bfdd597. Date Accessed October 6, 2026.
Linagliptin: MedlinePlus Drug Information. https://www.medlineplus.gov/druginfo/meds/a611036.html. Date Accessed October 6, 2026.
Metformin: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a696005.html. Date Accessed October 6, 2026.